Biofrontera appoints Dr. Heikki Lanckriet to Board under settlement with major stockholder

Biofrontera Inc.

Dr. Heikki Lanckriet appointed to Board of Directors effective July 7, 2023 as Class I director through 2025 annual meeting.
Nominated by Biofrontera AG under April 2023 settlement agreement between the companies.
Compensation: $40,250 annual retainer (pro-rated for 2023) plus annual stock award.
Lanckriet serves as CEO/CSO of 4basebio PLC and on Biofrontera AG's Supervisory Board.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Heikki Lanckriet

Director

BFRI · Biofrontera Inc.

Effective: 2023-07-07
Filed: July 12, 2023, 7:59 PM ET

On July 7, 2023, the board of directors (the “Board”) of Biofrontera Inc. (the “Company”) appointed Heikki Lanckriet to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Heikki Lanckriet was appointed as Director at Biofrontera Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 7, 2023, the board of directors (the “Board”) of Biofrontera Inc. (the “Company”) appointed Heikki Lanckriet to the Board.

View on SEC.gov

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-024286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.